IBDEI2GK ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,39256,1,4,0)
 ;;=4^E05.90
 ;;^UTILITY(U,$J,358.3,39256,2)
 ;;=^5002492
 ;;^UTILITY(U,$J,358.3,39257,0)
 ;;=E05.91^^152^1993^40
 ;;^UTILITY(U,$J,358.3,39257,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39257,1,3,0)
 ;;=3^Thyrotoxicosis,Unspec w/ Thyrotoxic Crisis/Storm
 ;;^UTILITY(U,$J,358.3,39257,1,4,0)
 ;;=4^E05.91
 ;;^UTILITY(U,$J,358.3,39257,2)
 ;;=^5002493
 ;;^UTILITY(U,$J,358.3,39258,0)
 ;;=E89.0^^152^1993^32
 ;;^UTILITY(U,$J,358.3,39258,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39258,1,3,0)
 ;;=3^Postprocedural Hypothyroidism
 ;;^UTILITY(U,$J,358.3,39258,1,4,0)
 ;;=4^E89.0
 ;;^UTILITY(U,$J,358.3,39258,2)
 ;;=^5003035
 ;;^UTILITY(U,$J,358.3,39259,0)
 ;;=E03.2^^152^1993^13
 ;;^UTILITY(U,$J,358.3,39259,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39259,1,3,0)
 ;;=3^Hypothyroidism d/t Meds/Oth Exogenous Substances
 ;;^UTILITY(U,$J,358.3,39259,1,4,0)
 ;;=4^E03.2
 ;;^UTILITY(U,$J,358.3,39259,2)
 ;;=^5002471
 ;;^UTILITY(U,$J,358.3,39260,0)
 ;;=E03.9^^152^1993^14
 ;;^UTILITY(U,$J,358.3,39260,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39260,1,3,0)
 ;;=3^Hypothyroidism,Unspec
 ;;^UTILITY(U,$J,358.3,39260,1,4,0)
 ;;=4^E03.9
 ;;^UTILITY(U,$J,358.3,39260,2)
 ;;=^5002476
 ;;^UTILITY(U,$J,358.3,39261,0)
 ;;=E06.0^^152^1993^36
 ;;^UTILITY(U,$J,358.3,39261,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39261,1,3,0)
 ;;=3^Thyroiditis,Acute
 ;;^UTILITY(U,$J,358.3,39261,1,4,0)
 ;;=4^E06.0
 ;;^UTILITY(U,$J,358.3,39261,2)
 ;;=^2692
 ;;^UTILITY(U,$J,358.3,39262,0)
 ;;=E06.1^^152^1993^37
 ;;^UTILITY(U,$J,358.3,39262,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39262,1,3,0)
 ;;=3^Thyroiditis,Subacute
 ;;^UTILITY(U,$J,358.3,39262,1,4,0)
 ;;=4^E06.1
 ;;^UTILITY(U,$J,358.3,39262,2)
 ;;=^119376
 ;;^UTILITY(U,$J,358.3,39263,0)
 ;;=C73.^^152^1993^19
 ;;^UTILITY(U,$J,358.3,39263,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39263,1,3,0)
 ;;=3^Malig Neop of Thyroid Gland
 ;;^UTILITY(U,$J,358.3,39263,1,4,0)
 ;;=4^C73.
 ;;^UTILITY(U,$J,358.3,39263,2)
 ;;=^267296
 ;;^UTILITY(U,$J,358.3,39264,0)
 ;;=E16.2^^152^1993^10
 ;;^UTILITY(U,$J,358.3,39264,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39264,1,3,0)
 ;;=3^Hypoglycemia,Unspec
 ;;^UTILITY(U,$J,358.3,39264,1,4,0)
 ;;=4^E16.2
 ;;^UTILITY(U,$J,358.3,39264,2)
 ;;=^5002708
 ;;^UTILITY(U,$J,358.3,39265,0)
 ;;=E20.0^^152^1993^15
 ;;^UTILITY(U,$J,358.3,39265,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39265,1,3,0)
 ;;=3^Idiopathic Hypoparathyroidism
 ;;^UTILITY(U,$J,358.3,39265,1,4,0)
 ;;=4^E20.0
 ;;^UTILITY(U,$J,358.3,39265,2)
 ;;=^5002712
 ;;^UTILITY(U,$J,358.3,39266,0)
 ;;=E20.9^^152^1993^11
 ;;^UTILITY(U,$J,358.3,39266,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39266,1,3,0)
 ;;=3^Hypoparathyroidism,Unspec
 ;;^UTILITY(U,$J,358.3,39266,1,4,0)
 ;;=4^E20.9
 ;;^UTILITY(U,$J,358.3,39266,2)
 ;;=^5002714
 ;;^UTILITY(U,$J,358.3,39267,0)
 ;;=E23.0^^152^1993^12
 ;;^UTILITY(U,$J,358.3,39267,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39267,1,3,0)
 ;;=3^Hypopituitarism
 ;;^UTILITY(U,$J,358.3,39267,1,4,0)
 ;;=4^E23.0
 ;;^UTILITY(U,$J,358.3,39267,2)
 ;;=^60685
 ;;^UTILITY(U,$J,358.3,39268,0)
 ;;=E27.1^^152^1993^34
 ;;^UTILITY(U,$J,358.3,39268,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39268,1,3,0)
 ;;=3^Primary Adrenocortical Insufficiency
 ;;^UTILITY(U,$J,358.3,39268,1,4,0)
 ;;=4^E27.1
 ;;^UTILITY(U,$J,358.3,39268,2)
 ;;=^5002740
 ;;^UTILITY(U,$J,358.3,39269,0)
 ;;=E27.2^^152^1993^1
